Deutsche Märkte geschlossen

Adocia SA (A89.F)

Frankfurt - Frankfurt Verzögerter Preis. Währung in EUR
Zur Watchlist hinzufügen
8,32-0,17 (-2,00%)
Ab 05:20PM CEST. Markt geöffnet.

Adocia SA

115 Avenue Lacassagne
Lyon 69003
France
33 4 72 61 06 10
https://www.adocia.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter97

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Dr. Gérard Soula M.B.A., Ph.D.Co-Founder & Chairman of the Board370,62kN/A1945
Mr. Olivier Soula M.B.A., Ph.D.Co-Founder, CEO & Director278,63kN/A1970
Ms. Valérie DanaguezianChief Financial OfficerN/AN/AN/A
Jeremy Benattar Eng., Pharm.D.Marketing & Strategy DirectorN/AN/AN/A
Ms. Geraldine Favre SoulaHuman Resources Development DirectorN/AN/AN/A
Dr. Bertrand AlluisHead of the Analysis Department and Project ManagerN/AN/AN/A
Dr. David DuracherHead of the Pharmaceutical Development & Physical Chemistry Departments and Project ManagerN/AN/AN/A
Dr. Richard CharvetHead of Chemistry Department & Project ManagerN/AN/AN/A
Dr. Grégory MeiffrenHead of the Biology Department & Project ManagerN/AN/AN/A
Rosy Eloy M.D.Chief Medical OfficerN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and BioChaperone GluExe, a combination of glucagon and exenatide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.

Corporate Governance

Adocia SAs ISS Governance QualityScore, Stand 1. April 2024, lautet 10. Die grundlegenden Scores sind Audit: 10, Vorstand: 10, Shareholderrechte: 9, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.